Fara Brasó-Maristany

Grup de recerca

Genòmica translacional i teràpies dirigides en tumors sòlids Post-doctoral researcher (R2A)

fbraso@recerca.clinic.cat 0000-0001-5440-9643

Publicacions destacades

Gene expression profiles of breast cancer metastasis according to organ site

Autors:
Braso-Maristany, Fara; Pare, Laia; Chic, Nuria; Martinez-Saez, Olga; Pascual, Tomas;

(...)

Adamo, Barbara; Moreno, Reinaldo; Vidal, Maria; Munoz, Montserrat; Prat, Aleix.

Referència: Molecular Oncology 2022.
Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer

Autors:
Brasó-Maristany F; Sansó M; Chic N; Martínez D; González-Farré B;

(...)

Peg V; Saura C; Muñoz M; Prat A; Vivancos A .

Referència: Frontiers In Oncology 2021.
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT

Autors:
Chic, Nuria; Schettini, Francesco; Braso-Maristany, Fara; Sanfeliu, Esther; Adamo, Barbara;

(...)

Munoz, Montserrat; Perou, Charles M; Pascual, Tomas; Bellet, Meritxell; Prat, Aleix.

Referència: Ebiomedicine 2021.
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

Autors:
Prat, A; Chaudhury, A; Solovieff, N; Paré, L; Martinez, D;

(...)

Brasó-Maristany, F; Lteif, A; Taran, T; Babbar, N; Su, F.

Referència: Journal Of Clinical Oncology 2021.
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

Autors:
Martinez-Saez, Olga; Pascual, Tomas; Braso-Maristany, Fara; Chic, Nuria; Gonzalez-Farre, Blanca;

(...)

Salvador, Fernando; Ciruelos, Eva M; Faull, Iris; Odegaard, Justin I; Prat, Aleix.

Referència: Npj Breast Cancer 2021.
A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer

Autors:
Prat, Aleix; Tsai, Yi-Hsuan; Pascual, Tomas; Pare, Laia; Adamo, Barbara;

(...)

Brase, Jan Christoph; Rodrik-Outmezguine, Vanessa; Johnston, Stephen; Ciruelos, Eva; Parker, Joel S.

Referència: Clinical Cancer Research 2020.
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

Autors:
Griguolo, Gaia; Braso-Maristany, Fara; Gonzalez-Farre, Blanca; Pascual, Tomas; Chic, Nuria;

(...)

Dieci, Maria Vittoria; Conte, Pierfranco; Harbeck, Nadia; Guarneri, Valentina; Prat, Aleix.

Referència: Cancers 2020.
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Autors:
Brasó-Maristany F.; Griguolo G.; Pascual T.; Paré L.; Nuciforo P.;

(...)

Gomis R.R.; Villagrasa P.; Cortés J.; Ciruelos E.; Prat A..

Referència: Nature Communications 2020.
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

Autors:
Prat A; Pascual T; De Angelis C; Gutierrez C; Llombart-Cussac A;

(...)

Conte P; Schiff R; Guarneri V; Osborne CK; Rimawi MF.

Referència: Journal Of The National Cancer Institute 2020.
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer

Autors:
Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J;

(...)

Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN .

Referència: Nature Medicine 2016.

Projectes destacats

Identification and validation of therapeutic targets to overcome resistance to CDK4/6 inhibitors in metastatic hormone receptor-positive HER2-negative breast cancer.

Investigador/a principal: Fara Brasó Maristany

Finançador: Fundación Científica Asociación Española Contra el Cáncer (AECC).

Codi: INVES21943BRAS

Durada: 01/12/2021 - 30/11/2024
Estudio de los mecanismos de sensibilidad y resistencia al doble bloqueo HER2 y a las combinaciones con enzalutamida o palbociclib en modelos preclínicos de cáncer de mama HER2-positivo

Investigador/a principal: Aleix Prat

Finançador: Asociación Española Contra el Cáncer (AECC) ; Fundación Científica Asociación Española Contra el Cáncer (AECC).

Codi: Ayuda Postdoctoral AECC 2017

Durada: 01/11/2017 - 31/10/2021

Web: https://www.aecc.es/es/investigacion/proyectos-aecc/estudio-mecanismos-sensibilidad-resistencia-doble-bloqueo-her2-combinaciones-con-enzalutamida-o-palbociclib-modelos-preclinicos-cancer-mama-her2

Fara Brasó-Maristany

Grup de recerca

Publicacions destacades

Projectes destacats

Identification and validation of therapeutic targets to overcome resistance to CDK4/6 inhibitors in metastatic hormone receptor-positive HER2-negative breast cancer.

Estudio de los mecanismos de sensibilidad y resistencia al doble bloqueo HER2 y a las combinaciones con enzalutamida o palbociclib en modelos preclínicos de cáncer de mama HER2-positivo

Subscriu-te a la Newsletter del Clínic